


Alzheimer Society International Congress 2019

ASIC 2019

February 18 - 21, 2019

San Francisco Airport Crowne Plaza



WELCOME



The 1st Alzheimer Society International Congress

February 18-21, 2019

San Francisco Airport Crowne Plaza

San Francisco, California, USA

<http://www.alzint.com>

ASIC 2019™ CONFERENCE THEME:

“United Front Against Alzheimer’s”

ASIC 2019 will highlight the latest accomplishments in Alzheimer research and best practice in patient care.

ASIC 2019 presents new concepts on the etiology, potential prevention or treatment therapy, and best practice in Dementia care.

NEW FEATURES OF THE ASIC 2019:

- Presenting latest findings in Alzheimer research and best practices in dementia patient care.
- Featuring alternative approaches to the amyloid hypothesis.
- Launching the UNITED FRONT AGAINST ALZHEIMER’S, to fund innovative approaches and clinical trials in Alzheimer’s.
- Formulating a new strategy to find a prevention or a treatment of Alzheimer’s by 2025.
- Introducing the GLOBAL VIRTUAL ALZHEIMER COMMUNITY to collaborate in research and practices in dementia patient care.

TOPICS

- Genetics
- Molecular and Cell Biology
- Diagnosis and Prognosis
- Neuroimaging
- Neuropathology
- Neuropsychiatry
- Dementia Care Research
- Bioinformatics and Computational Biology
- Health Economics and Policy
- Non-Pharmaceutical Prevention
- Psychosocial Factors and Environment Design
- New Models and Methods
- Preclinical Research
- Human Clinical Trials

Dear colleagues:

We are pleased to welcome you to the 1st Alzheimer Society International Congress (ASIC 2019), San Francisco, February 18-21, 2019.

Alzheimer’s Disease is a progressive and irreversible neurodegenerative disorder that affects millions of people worldwide. Today, more than 5.8 million people in the United States and 45 million people worldwide live with Alzheimer’s. There is currently no cure, no prevention and no treatment of Alzheimer’s disease.

If Dr. Alois Alzheimer were alive today, he would not be able to offer any other treatment to his senile patients than what he provided in the beginning of 1900. Why, after 115 years, FDA (Food and Drug Administration), EMA (European Medicines Agency) and other regulatory agencies in the world are not approving any Alzheimer’s disease modifying drugs and other treatment options?

ASIC 2019 is an open forum to foster interaction, share knowledge and make a difference in our understanding and treatment of Alzheimer’s disease and dementia care. Over the past 40 years since the NIH began funding in research on Alzheimer in 1978, there have been over 150 drug compounds tested as potential therapies were identified that were either abandoned or failed in more than 400 clinical trials.

The Alzheimer International Society and our partners have declared war on Alzheimer’s disease. At the ASIC 2019 we have launched the United Front Against Alzheimer’s, which calls for global research collaboration to accelerate the discovery and development of preventive methods and treatment therapies of Alzheimer’s disease.

We thank our program committee members and volunteers, who have done so much in organizing ASIC 2019. We appreciate our speakers, presenters and groups of sponsors and exhibitors in making the ASIC 2019 program possible. Thank you all for attending and making ASIC 2019 an unforgettable event. Together we can draw the roadmap of Alzheimer research and dementia care, so that others coming after us will be able to carry on to fight the fight.

With warmest regards,

Markku Kurkinen and Lloyd L. Tran

Program Co-Chairs

Alzheimer Society International Congress 2019



Alzheimer International Society

1159 Sonora Court, Suite 345

Sunnyvale, CA 94086 USA

Tel. 1-650-826-2337 - <http://www.alzint.com>

PROGRAM SCHEDULE

Alzheimer Society International Congress
February 18-21, 2019, San Francisco



MONDAY FEBRUARY 18, 2019

12:00 PM- 05:00 PM	Registration
01:00 PM- 05:00 PM	Exhibitor Set-up
01:00 PM- 04:00 PM	Workgroup: "The Neuroimmune Nexus of Depression and Dementia: Shared Mechanisms and Therapeutic Targets"
01:00 PM- 01:05 PM	Introduction and Welcome Remarks from Co-Chairs
01:05 PM- 01:30 PM	Prof. Giulio M. Pasinetti Icahn School of Medicine at Mount Sinai New York, NY <i>"Shared Immune Pathways in Major Depressive Disorder and Dementia"</i>
01:30 PM- 02:00 PM	Dr. Sunnie Kenowsky New York University School of Medicine New York, NY <i>"Depression, Dementia, and Antidepressant usage: What's the Controversy and Where Are We Now?"</i>
02:00 PM- 02:30 PM	Dr. Sudeshna Das Massachusetts General Hospital Boston, Massachusetts <i>"Role of the Microglia in Alzheimer's Disease: A Genomics Perspective"</i>
02:30 PM- 02:45 PM	Coffee Break
02:45 PM- 03:15 PM	Dr. Chad Smith Icahn School of Medicine at Mount Sinai New York, NY <i>"Targeting the NLRP3 Inflammasome in the Mechanism of Sleep Deprivation Induced Neuroinflammation"</i>
03:15 PM- 03:45 PM	Ms. Alice La University of California San Francisco San Francisco, California <i>"Slow wave sleep enhancers in delaying cognitive decline: the case for trazodone"</i>
03:45 PM - 4:00 PM	Roundtable Panel Discussion
04:30 PM- 05:15 PM	Depart the SFO Crowne Plaza for Fisherman's Wharf in San Francisco
05:30 PM- 07:30 PM	Sunset Bay Cruise San Francisco
08:30 PM- 09:00 PM	Return to Crowne Plaza Hotel

TUESDAY FEBRUARY 19, 2019

07:00 AM- 08:00 AM	Registration
08:00 AM- 08:30 AM	Breakfast
08:30 AM- 08:35 AM	Welcome Remark from Program Co-chairs
	Session Chair: Lloyd L. Tran , Program Co-Chair
08:40 AM -10:00 AM	Keynote Session and Panel Discussion on <i>"After 40 year of research failure in Alzheimer's- Where are we headed?"</i>
	Markku Kurkinen , Program Co-Chair, Professor, Wayne State University School of Medicine, Michigan, USA
	Lloyd L. Tran , Program Co-Chair Chairman, NeuroActiva Inc. California, USA
	Les Hamasaki , Director, Alzheimer International Society California, USA
	Bryce Vissel Director, Centre for Neuroscience and Regenerative Medicine, University of Technology Sydney, NSW, AUSTRALIA
	Giulio M Pasinetti The Saunders Family Chair and Professor of Neurology, Icahn School of Medicine at Mount Sinai, New York, USA
	Leen Kawas CEO, M3 Biotechnology Seattle, Washington, USA
10:00 AM- 10:30 AM	Coffee Break- Exhibit and Poster Presentation
	Session Chair: Rui-Ming Liu Univ. of Alabama, Birmingham, AL, USA
10:30 AM- 10:50 AM	Kai C. Sonntag , Woo-In RYU, Wang, LIAO, Ryan A HEALY, Minqi SHEN, Mariana K BORMANN, Hyemyung SEO, Bruce M COHEN Department of Psychiatry, McLean Hospital, Harvard Medical School- Boston, Massachusetts, USA <i>"Aberrant Cellular Bioenergetics is an Inherent Key Feature in Alzheimer's Disease"</i>
10:55 AM- 11:15 AM	Yoshitaka Tatebayashi , Naomi Nihonmatsu- Kikuchi, Yoshiki Matsuda, Kazuhisa Aoki, and Toshiki Uchihara Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, JAPAN <i>"Essential roles of plexin-B3+ oligodendrocyte progenitor cells in the pathogenesis of Alzheimer's disease"</i>



PROGRAM SCHEDULE

Alzheimer Society International Congress
February 18-21, 2019, San Francisco



TUESDAY FEBRUARY 19, 2019

The Conference Schedule may be subject to changes

11:20 AM- 11:40 AM

Chunjiu Zhong, Shaoming Sang, Xiaoli Pan, Lijun Wang, Wenbin Wan, Changpeng Wang, Ting Qian, Zigao Wang and Xiaoqin Cheng.
Department of Neurology, Zhongshan Hospital, State Key Laboratory of Medical Neurobiology and Institutes for Brain Science, Fudan University, Shanghai, CHINA
"Decoding Alzheimer's disease based on brain glucose hypometabolism: From bench to bedside."

11:45 AM- 12:05 PM

Lew Lim
Vielight Inc.,
Reza Zomorodi, Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health; Toronto Ontario, Canada, Genane Loheswaran, Vielight Inc, Canada, Abhiram Pushparaj, Ironstone Product Development Inc., Toronto, Ontario, CANADA
"Gamma-pulsed Transcranial Photobiomodulation Produces Desired EEG Measures applicable for Alzheimer's Disease treatment."

12:10 PM- 01:30 PM

Lunch- Exhibit and Poster Presentation

Session Chair: Markku Kurkinen
Program Co-Chair

01:30 PM- 01:50 PM

Herbert Allen and Suresh G. Joshi
Drexel University College of Medicine, Philadelphia, PA, USA
"The leading role of spirochetes in Alzheimer's disease"

01:55 PM- 02:15 PM

Elizabeth Milward, Ritambhara Aryal¹, Jason J. Woods¹, Elvis Freeman-Acquah¹, Kristy L. Martin¹, Seak-Lin Ly¹, Samuel Kelsey¹, and Daniel M Johnstone².
¹ School of Biomedical Sciences and Pharmacy, University of Newcastle, NSW, AUSTRALIA
² Bosch Institute and Discipline of Physiology, University of Sydney, NSW, AUSTRALIA .
"The Relationship of Iron and Amyloid: Insights from A New Mouse Model of Iron-Loading and Amyloidosis."

02:20 PM- 02:40 PM

Linda L. Chao
University of California, San Francisco & San Francisco VA Medical Center San Francisco, CA, USA
"Effects of Photobiomodulation on Cognitive Function, Cerebral Perfusion and Functional Connectivity in Patients with Dementia"

02:45 PM- 03:05 PM

Sudeshna Das, Emily M. Merrill, Nathan A. Bihlmeyer, Yann Lambert, Gyan P. Srivastava, Timothy W. Clark and Bradley T. Hyman
Department of Neurology, Massachusetts General Hospital and Harvard Medical

03:05 PM- 03:30 PM

School Cambridge, MA, USA
"Integrative Omics Analysis to Investigate the Ca²⁺ Signaling Pathway in Alzheimer's Disease"

Session Chair: Jerzy Leszek
Wroclaw Medical University Dept. of Psychiatry, Wroclaw, POLAND

03:30 PM- 03:50 PM

Valentin Bragin
Stress Relief and Memory Training Center- Brooklyn, NY, USA
"A multi-faceted rehabilitation model in Alzheimer's disease in the context of adjustable and modifiable factors"

03:55 PM- 04:15 PM

Medha Kothari, Prasanta Dey and Ian Maidment
Aston University, Birmingham, UK
"Using Six Sigma Strategy, DMAIC to Improve the Dementia Medicines Management Process within UK Care Homes Using Six Sigma Strategy, DMAIC to Improve the Dementia Medicines Management Process within UK Care Homes"

04:20 PM-04:40 PM

Elizabeth Barber
Barber Innovations LLC
Winfield, IL USA
"Therapeutic Benefits of Art, Structure and Nutrition for the Parkinson's Patient with Alzheimer's Changes."

04:45 PM- 05:15 PM

Discussion- Conclusion of Day 1



- Deep domain expertise in biopharmaceutical industry.
- Great experience and insight in building great companies
- Breakthrough therapies for un-met needs
- Lead investor in the United Front Against Alzheimer's

www.TranspacificVC.com

PROGRAM SCHEDULE

Alzheimer Society International Congress
February 18-21, 2019, San Francisco



WEDNESDAY FEBRUARY 20, 2019

The Conference Schedule may be subject to changes

07:00 AM- 04:00 AM	Registration	11:35 AM- 11:55 AM	Xinhua Zhan , Boryana Stamova and Frank R. Sharp. Department of Neurology, MIND Institute, University of California at Davis, CA, USA <i>"Lipopolysaccharide associates with damaged myelin in Alzheimer's Disease brain"</i>
07:00 AM- 08:00 AM	Breakfast		
08:00 AM- 08:10 AM	Welcome remarks from the Program Co-Chairs		
	Session Chair: Bryce Vissel University of Technology Sydney, NSW, AUSTRALIA	11:55 AM- 12:15 PM	Shauna Yuan , Charisse N. Winston ¹ , Brent Aulston ¹ , Edward M. Rockenstein ¹ , Anthony Adame ¹ , Olga Prikhodko ¹ , Kishan N. Dave ¹ , Priyanka Mishra ¹ , Robert A. Rissman ^{1,2} ¹ Departments of Neurosciences, University of California, San Diego, La Jolla, CA, USA ² Veterans Affairs San Diego Healthcare System, La Jolla, CA, USA <i>"Neuronal exosome-derived human tau is toxic to recipient mouse neurons in vivo"</i>
08:15 AM- 08:35 AM	Markku Kurkinen Wayne State University School of Medicine Detroit, MI, USA <i>"Alzheimer's drugs: Targeting synaptic glutamate uptake"</i>		
08:40 AM- 09:00 AM	Rui-Ming Liu , Chunsun Jiang, Luke T. Stewart, Hui-Chien Kuo, William McGilberry, Stephanie B. Walld, Bill Liang, Thomas van Groen, Shannon M. Bailey, Young-il Kim, Trent E. Tipple, Dean P. Jones, and Lori L. McMahon University of Alabama, Birmingham, AL, USA <i>"Cyclic O3 exposure synergizes with aging leading to memory impairment in APOEε3, but not APOEε4, targeted replacement male mice"</i>	12:15 PM- 01:30 PM	Lunch- Exhibit and Poster Presentation
		01:30 PM- 02:15 PM	Session Chair: Elizabeth Milward University of Newcastle, NSW, AUSTRALIA
09:05 AM- 09:25 AM	Yu-Wen Alvin Huang , Bo Zhou, Marius Wernig, and Thomas Sudhof Stanford University School of Medicine Stanford, CA, USA <i>"APOE2, E3 and E4 differentially activate MAP-kinase signaling to regulate amyloid-beta secretion and synapse formation paralleling their role in Alzheimer's disease"</i>		A presentation from the United States-National Institute of Aging Todd Haim Chief of the Office of Small Business Research, National Institute on Aging (NIH/ NIA) <i>"Funding Opportunities from the National Institute of Aging (NIA)"</i>
		02:20 PM- 02:40 PM	Christopher Heye , Anthony Weiner ¹ , Janet Sherman ² , Lee Baer ¹ , Maurizio Fava ¹ Cogniscent, Inc ¹ Department of Psychiatry, Massachusetts General Hospital, ² Department of Psychiatry, Psychology Assessment Center, Massachusetts General Hospital, <i>"Aging, Diminished Capacity, and Financial Decision-making"</i>
09:30 AM- 09:50 AM	Rammohan Rao AffirmativHealth Sonoma, CA, USA <i>"Transcriptional Effects of APOEε4: Relevance to Alzheimer's Disease"</i>		Claudia Jacova , Samantha Smith and Sara Wong School of Graduate Psychology, Pacific University Hillsboro, OR, USA <i>"Subjective cognitive decline and worries about outcomes independently predict the acceptance of screening"</i>
09:50 AM- 10:15 AM	Coffee Break- Exhibit and Post Presentation	02:45 PM- 03:05 PM	
	Session Chair: Herbert Allen Drexel University College of Medicine, Philadelphia, PA, USA	03:05 PM- 03:30 PM	Coffee Break – EXHIBIT and POSTER PRESENTATION
10:20 AM- 10:40 AM	Lloyd Tran et al. NeuroActiva, Inc. San Jose, CA, USA <i>"A Randomized Double-Blind Placebo-Controlled Phase 2A Clinical Trial of NA-831 in Patients with Mild Cognitive Impairment and early stage of Alzheimer's Disease"</i>		Session Chair: Linda Chao University of California, San Francisco & VA Medical Center
		03:30 PM- 03:50 PM	Jo Ann Pelaez-Fisher The College of Southern Nevada Las Vegas, NV, USA <i>"Assessment of the cultural competence, dementia attitude and Alzheimer's disease knowledge among tertiary healthcare providers"</i>
10:45 AM- 11:05 AM	Jerzy Leszek Wroclaw Medical University Dept. of Psychiatry, Wroclaw, POLAND <i>"Alzheimer's Disease- Future Therapy Based on Dendrimers"</i>		
11:10 AM- 11:30 AM	Man Shing Wong , Yinhui Li, Di Xu, Hei-Nga Chan, See-Lok Ho, and Hung-Wing Li Department of Chemistry, Hong Kong Baptist University, Hong Kong, SAR CHINA <i>"NIR/MR Dual-Modal Nanoparticle-Based Contrast Agent for Amyloid-β Imaging in Mouse Model"</i>	03:55 PM- 04:15 PM	Jason Woods ¹ , Kristy Martin ¹ , Ritambhara Aryal ¹ , Jay Horvat ² , Daniel M Johnstone ³ , Phillip Hansbro ² , and Elizabeth A Milward ¹ ¹ School of Biomedical Sciences and Pharmacy, University of Newcastle, NSW, Australia. ² Hunter Medical Research

PROGRAM SCHEDULE

WEDNESDAY FEBRUARY 20, 2019



THURSDAY FEBRUARY 21, 2019

04:20 PM- 04:40 PM

Institute, NSW, AUSTRALIA
³ Bosch Institute and Discipline of Physiology, University of Sydney, NSW, AUSTRALIA
"Studies In Improved Models Of Neonatal and Adult Experimental Respiratory Chlamydia Infection Do Not Support Causative Roles For Chlamydia In Alzheimer's Disease"

Nathan Duval, Alex Sandberg, Srivalli Puttagunta and Daniel Linseman, Knoebel Institute for Healthy Aging University of Denver, Denver, CO, USA
"Treatment with Immunocal, a cysteine-rich whey protein supplement, elevates reelin expression and signaling and ameliorates Alzheimer's disease-like pathology in a mouse model of Alzheimer's disease"

04:45 PM- 05:15 PM


Discussion- Conclusion of day 2



NA-831 (Traneurocin)

- Exhibits Neuroprotection and Neurogenesis
- High bioavailability, crossing the Blood Brain Barrier
- It is safe, no adverse affects
- Available in both injectable and oral formulations
- Demonstrated safety, improvement of cognitive and memory functions in Phase 2A with Alzheimer's patients

MICROS Controlled Release Drug Delivery System



A portable infusion pump for outpatient care, which has been approved by the FDA for Marketing in the USA

www.neuroactiva.com

07:00 AM- 02:00 PM

Registration

07:00 AM- 08:00 AM

Breakfast

08:00 AM- 08:10 AM

Welcome remarks from the Program Co-Chair

Session Chair: Bryce Vissel

University of Technology Sydney, NSW, AUSTRALIA

08:15 AM- 08:35 AM

Umur Kayabasi

Bahcesehir University, Istanbul, TURKEY
 John Rose, OD- John Rose Eye Center, London, UK
"Imaging Misfolded Tau in the Retina"

08:40 AM- 09:00 AM

James Moe¹, Eliot J. Davidowitz¹, Pavan Krishnamurthy¹, Patricia Lopez¹, Heidi Jimenez², Leslie Adrien², Peter Davies²
¹ Oligomerix, Inc., Bronx, NY, USA
² The Litwin-Zucker Research Center for the Study of Alzheimer's Disease, The Feinstein Institute of Medical Research, Northwell Health, Manhasset, NY, USA
"In vivo validation of a small molecule inhibitor of tau oligomer formation in htau mice"

09:05 AM- 09:25 AM

Elena Paley

Expert Biomed, Inc. & Stop Alzheimer Corp. Homestead, FL USA
"Link of human gut bacterial sequence (ADAS) with Alzheimer's and associated diseases: ADAS-associated prevalence of fecal metabolites in health and disease"

09:30 AM- 09:50 AM

Zung Tran, Anna Ivashchenko, William KENT and Kate Yzquierdo
 Medaware Systems, Inc. Broomfield, CO, USA
"Effects of donepezil (Aricept) on cognitive impairment in Alzheimer's disease and dementia: Multiple instrumentations hinder outcomes assessment"

09:55 AM- 10:15 AM

Harry Goldsmith

University of California, Davis—Retired Glenbrook, NV, USA
"Omental Transposition to the Brain of Alzheimer Patients"

10:15 AM- 10:30 AM

Coffee Break

Session Chair: Lloyd L. Tran

Program Chair

10:30 AM- 10:50 AM

Federico Goodsaid,³Harald Hampel,¹ Mohammad Afshar², Frédéric Parmentier², Coralie Williams², Adrien Etcheto², Christopher U Missling⁴
¹Department of Neurology, Sorbonne University, Paris, France, ²Ariana Pharma, Paris, France, ³Regulatory Pathfinders LLC, San Francisco, CA, ⁴Anavex Life Sciences Corp., New York, NY
"Longitudinal 148-Week Extension Study for ANAVEX®2-73 Phase 2a Alzheimer's Disease Demonstrates Maintained Activities of Daily Living Score (ADCS-ADL) and Reduced Cognitive Decline (MMSE) for Patient Cohort on Higher Drug Concentration and Confirms Role of Patient Selection Biomarkers"

PROGRAM SCHEDULE

Alzheimer Society International Congress
February 18-21, 2019, San Francisco



THURSDAY FEBRUARY 21, 2019

The Conference Schedule may be subject to changes

10:55 AM- 11:15 AM

Sunnie Kenowsky¹, Yongzhao Shao², Carol Torossian³, Muhammad Saad³, Gianna Dafflisio³, Alok Vedvyas⁴, and Barry Reisberg³

¹ Department of Psychiatry, New York University School of Medicine, New York University Langone Health

² Departments of Population Health and Environmental Medicine, New York University Langone Health

³ Department of Psychiatry, New York University School of Medicine, New York University Langone Health

⁴ Department of Neurology, New York University Langone Health

"Effect of Comprehensive, Individualized, Person-Centered Management on Antidepressant's Usage in Advanced Alzheimer's Persons in a 28-Week, Randomized, Controlled Trial"

11:20 AM- 11:40 AM

Bruno Bonnechère

Laboratory of Anatomy, Biomechanics and Organogenesis, Université Libre de Department of Electronics and Informatics, VUB, Brussels, BELGIUM

"Can we learn by playing? An ecological study using mobile games"

11:45 AM-12:05 PM

Lon White¹, Steven Edland², Julia Chosy¹, Margaret Flanagan³, Brenna Cholerton⁴, Laura Hemmy³, and Tom Montine⁴

¹Pacific Health Research and Education Institute, Honolulu, HI, USA

²University of California at San Diego;

³University of Minnesota School of Medicine

⁴Stanford University School of Medicine

"Development and use of a resilience index to identify protective factors"

12:10 PM-1:15 PM

Lunch

Session Chair: Xinhua Zhan,

Department of Neurology, University of California at Davis, Davis, CA, USA

1:15 PM- 1:35 PM

Katrin Schenk¹, Eleanore Bayen², Natalie Manley³, Tamary Braley³, Jennifer Merrilees², Amy Clark³, Brad Zylstra¹, Michael, Schaffer², Alex Bayen⁴, Katherine Possin², Bruce Miller², and Stephen Bonasera³

¹ Department of Physics, Randolph College, Lynchburg, VA, USA

² Memory and Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.

³ Division of Geriatrics, Department of Internal Medicine, University of Nebraska Medical Center, Omaha NE, USA.

⁴ Department of Civil and Environmental Engineering, University of California, Berkeley, Berkeley, CA, USA

"Patterns of lifespaces and physical activity from persons with Alzheimer's disease and dementia provide insight into caregiver challenges and successes"

01:40 PM – 02:00 PM

Van Park

University of California at San Francisco (UCSF), School of Nursing, Department of Community Health Systems, San Francisco, CA USA

Vy Ton, San Jose State University, Department of Health Science and Recreation; Gwen Yeo, Stanford University, School of Medicine; Quyen Tiet, California School of Professional Psychology at Alliant International University & National Center for PTSD, VA Palo Alto HCS; Quyen Vuong, International Children Assistance Network; and Dolores Gallagher-Thompson, Stanford University, School of Medicine San Francisco, CA, USA

"Culturally Tailored, Evidence-based Program for Vietnamese American Dementia Caregivers to Reduce Stress and Depression: A Randomized Control Trial"

02:00 PM- 04:00 PM

WORK SHOP: *"Effective Interventions for Depression in Dementia Family Caregivers: Review and Recommendations"*

02:00 PM- 02:30 PM

Barbara Sommer MD- Associate Professor in Psychiatry, Emerita Dept. of Psychiatry & Behavioral Sciences Stanford Univ. School of Medicine

"Psychiatric Treatment of the Patient with Dementia: Concerns in Treating the Caregiver"

02:30 PM- 03:00 PM

Rita Ghatak, Ph.D- Former Director, Stanford Aging Adult Services. Associate Director, Optimal Aging Center *"Continuum of Care for Families Facing Dementia"*

03:00 PM- 03:15 PM

Coffee Break

03:15 PM- 03:45 PM

Dolores Gallagher-Thompson, PhD, ABPP

Board Certified in Clinical Psychology and Geropsychology Professor Emerita, Dept. of Psychiatry & Behavioral Sciences Stanford Univ. School of Medicine *"Using CBT and Other Forms of Psychotherapy to Reduce Depression in Family Caregivers."*

03:45 PM- 04:00 PM

Q&A Discussion

04:00 PM- 04:30 PM

Discussion- Conference Conclusion Meeting Adjourned



Alzheimer International Society
1159 Sonoma Court, Suite 345
Sunnyvale, CA 94086 USA

Tel. 1-650-826-2337 - <http://www.alzint.com>

POSTER PRESENTATIONS

POSTER PRESENTERS



Tuesday February 19 during morning coffee breaks, lunch and afternoon breaks.

Ram Bhatt, M. Sinkovich, O. Ramos, Herbert Chow
ICB International, Inc.
La Jolla, CA, USA
"Meeting the Unmet Medical Need for Neurodegenerative Diseases"

Phillip DiGiacomo, Samuel Webb, Ed Plowey, Maged Goubran, Sherveen Parivash, Brian Rutt, Don Born, Michael Zeineh
Stanford University
Stanford, CA, USA
"Altered oxidation state supports neuroinflammatory role of iron in Alzheimer's disease"

Ivan Fedoriv, Anna Fedoriv, Inna Fedoriv, Tkachuk Nazar, Anton Fedoriv, Olesya Fedoriv
Applied Nanobiotech Research Lab
Chernivtsi, Ukraine.
"Stabilization of Protein Prenylation is an Emerging Approach for Correcting Alzheimer's Diseases"
"New Metabolic Strategies for Bioethereal substance, functional genomics, isopentenyl tRNAs and resistance to Alzheimer's disease."

Nicole M. Gatto, Jennifer Garcia-Cano¹, Crissy Irani¹, Grace J. Lee²
¹Claremont Graduate University
²Loma Linda University
Claremont, CA USA
"Observed physical function is associated with better cognition among elderly adults: the Adventist Health Study"

Jordan M. Glenn, Nicholas T. Bott, Erica N. Madero, Alex Lange, John Anderson, Doug Newton, Adam Brennan, Elizabeth A. Buffalo, Dorene M. Rentz, Stuart M. Zola, NeuroTrack Technologies
Redwood City, CA, USA
"Remote Evaluation of Cognitive Function Using Eye Tracking Metrics from Device-Embedded Webcams"

Maribella González-Viruet¹, Elixmahir Dávila-Marrero², Deborah Pérez-Mojica²
¹Carlos Albizu University
²Private Practice
San Juan, Puerto Rico, USA
"Trail Making Test, the Case of the Island of Puerto Rico"

William Grant¹ and Conor P. Kerley²
¹ Sunlight, Nutrition and Health Research Center
San Francisco, CA USA
² Dept. of Paediatric Medicine, National Children's Hospital, Dublin, IRELAND
"Dietary risk-modifying factors for cognitive dysfunction, dementia, and Alzheimer's disease"

Qing Guo, Jun Xie, and Sima Asfa,
Department of Physiology, The University of Oklahoma Health Sciences Center
Oklahoma City, OK, USA
"Regulation of Neuronal Necroptosis By Sap-12 In Alzheimer's Disease"

Anne Koplin
SSM Health/Dean Medical Group
Milwaukee, WI, USA
"Behavioral Correlates of Cognitively Healthy Adults"

Goo Rak Kwon, Bijen Khagi, Moon-Soo Kang
Chosun University, Dong-Gu
Gwangju, Republic of Korea
"Alzheimer's diseases detection form Brain MRI using VBM and AAL extracted features"

Fidias E Leon-Sarmiento¹, Juan S. Leon-Ariza² and Daniel S. Leon-Ariza³
¹Univeristy of Pennsylvania, Philadelphia, PA, USA
²Medicencias Research Group, Louisville, KY, USA
³UDES, Bucaramanga, Colombia
"The orbicularis oculi reflexes in Alzheimer's disease: State of the evidence and meta-analysis"

Hung Wing Li, Hei-Nga Chan, Di Xu, See-Lok Ho, Dinggeng HE, Man Shing Wong
Department of Chemistry, Hong Kong Baptist University
Hong Kong, China
"Highly sensitive quantification of Alzheimer's disease biomarkers by aptamer- assisted amplification"

Ileana Lorenzini, Jennifer Levy, Camelia Burciu, Divya Bhatia, Benjamin Rabichow, Doug Clough, and Rita Sattler
Barrow Neurological Institute
Phoenix, Arizona, USA
Human in vitro co-culture system of C9orf72-FTD/ALS patient-derived iPSC neurons and microglial cells to study mechanisms of synaptopathy

Atul Sunny Luthra
McMaster University. Homewood Health Center
Hamilton, ON, CANADA
"A New Behavioural Assessment and Intervention Response Inventory: LuBAIR (in persons with dementia)"

Patricia Martín-Maestro¹, Andrew Sproul², Hector Martinez³, Dominik Paquet⁴, Marc Tessier-Lavigne⁵, Meri Gerges¹, Scott Noggle³, Anatoly AStarkov¹
¹ Feil Family Brain & Mind Research Institute. Weill Cornell Medicine. NY, USA.
² The New York Stem Cell Foundation. NY, USA.
³ The New York Stem Cell Foundation. NY, USA.
⁴ Institute for Stroke and Dementia Research. University Hospital. Munich, Germany.
⁵ Laboratory of Brain Development and Repair, The Rockefeller University, New York. Stanford University, Stanford, CA, USA.
"Autophagy induction by Bexarotene promotes mitophagy in Presenilin 1 familial Alzheimer's disease iPSC-derived neural stem cells"

POSTER PRESENTATIONS

POSTER PRESENTERS

Tuesday February 19 during morning coffee breaks, lunch and afternoon breaks.

Elias Michaelis, R. Pal, , H. Allen, B. S. J. Blagg, O. Mozziconacci, and C. Schöneich,
Higuchi Biosciences Center, University of Kansas
Kansas, USA
"Protection Against A β -Induced Neuronal Damage by an HSP90 C-terminal Modulator and the Importance of Pyruvate Dehydrogenase Kinase"

Sarah Nasrouel^{1,2}, Julina A. Rattel¹, Michael Liedlgruber¹, Josef Marksteiner², Frank H. Wilhelm¹
¹ Division of Clinical Psychology, Psychiatry, and Health Psychology, Department of Psychology, University of Salzburg, Salzburg, AUSTRIA
² Department of Psychiatry and Psychotherapy A, State Hospital Hall, Hall, AUSTRIA
"Fear Acquisition and Extinction Deficits: Prognostic Markers for Alzheimer's Disease?"

John Hall Olichney, Charlie DeCarli, Joshua Miller, David Johnson, Sarah Farias PhD, Bruce Hammock, Brittany Dugger, Lee-Way Jin, PhD, Mary McPhail-Cuifo, Kelsey Levinson, Robert Soohoo, Dan Mungas, Danielle Harvey
University of California, Davis
Sacramento, CA, USA
"Can vitamin D supplementation slow cognitive decline in Alzheimer's disease?"

Jose Rodriguez, Gomez Maribella, Gonzalez Viruet, Lizzette Roman Rosa, and J. Rodriguez Benitez
University of Puerto Rico
San Juan, PR, USA
"Vieques, Puerto Rico, an Island within an Island: A descriptive study of Cognitive Performance in a sample of people 60 years and older"

Ricardo Salazar, Indika V Mallawaarachchi, and Alok K. Dwivedi
Paul L Foster School of Medicine, Department of Psychiatry, Division of Geriatric Psychiatry and Behavioral Neurosciences
El Paso, TX, USA
"Cross-ethnic Differences in Peripheral Biomarkers Levels of Inflammatory Cytokines in Patients with Simultaneous Diagnosis of Alzheimer's disease Dementia and Type II Diabetes Mellitus"

Madhuvanthi Suresh
Abigail Kramer, & Sherry A. Beaudreau
Palo Alto Veterans Affairs Health Care System/Palo Alto University
Palo Alto, CA, USA
"Hearing Impairment and the Occurrence and Severity of Anxiety and Depressive Symptoms in Older Adults with Cognitive Impairment"

Tonita Wroolie¹, Valentina Ghisays², Katie Watson¹, Kewei Chen², Erick Riemann², Natalie L. Rasgon,¹
¹ Stanford University, School of Medicine
² Banner Institute
"Pro inflammatory lipids differentially affect cognitive function and regional cerebral metabolism in APOE4 carriers versus non-carriers"



PHOTO BIO MODULATION

Linda L. Chao
University of California,
San Francisco &
San Francisco VA Medical Center

**Effects of
Photobiomodulation on
Cognitive Function,
Cerebral Perfusion and
Functional Connectivity
in Patients with Dementia**

**Tuesday, February 19, 2019
2:20 PM - 2:40 PM**

A FUTURE MODALITY FOR ALZHEIMER'S

Lew Lim
Founder & CEO Vielight Inc.

**Gamma-pulsed Transcranial
Photobiomodulation
Produces Desired EEG
Measures Applicable
for Alzheimer's Disease
treatment**

**Tuesday, February 19, 2019
11:45 AM- 12:05 PM**

VIELIGHT
The Life Light®

CE IVD CC REP

Plasma Biomarkers of Dementia

IMR Assays

APPLICATIONS

- ▶ Early Stage (MCI) Diagnosis
- ▶ Substitution of CSF Test
- ▶ Atypical Dementia Differential Diagnosis
- ▶ Follow-up Monitor of Treatment
- ▶ Exclusion of Alzheimer's Disease
- ▶ Pre-screening for Brain Image Diagnosis (PET/MRI)

Ultra-Sensitive IMR Assay

Assay Items (Limit of Detection)

- ▶ α -synuclein (1.39 fg/ml)
- ▶ Phosphorylated α -Synuclein (0.065 fg/ml) *
- ▶ TDP-43 (0.12 fg/ml) *
- ▶ Total-Tau (0.026 pg/ml)
- ▶ Phosphorylated Tau (0.019 pg/ml)
- ▶ $A\beta_{1-42}$ (0.17 pg/ml)
- ▶ $A\beta_{1-43}$ (0.77 pg/ml)

* Research use only

Analyzer XacPro-S

磁量生技股份有限公司

MAGQU CO., LTD.

MAGQU LLC

3F, No. 12, Lane 538, Zhongxing Rd.,
Xindian District, New Taipei City 231, Taiwan

Tel.: +886 (2) 8607-1809
Fax: +886 (2) 8607-1806
Email: info@magqu.com

13-075 W. Hill Rd. Box 337
Sarasota, AZ 93776, USA
Tel.: +1 (931) 752-9888

www.magqu.com



We are pleased to announce the formation of Journal of the Alzheimer International Society (JAIS). This will be a fully open access journal, Internet-only journal, accessible to all involved or interested in the prevention and treatment of Alzheimer's disease and dementia care.

JAIS will be a general medical journal featuring scientific, medical, and health content in a wide range of subject areas including: Behavior Science, Epidemiology, Ethics, Genetics and Genomics, Geriatrics, Health Informatics, Health Policy, Imaging, Immunology, Neurology and Neuroscience, Neuroimaging, Neuropathology, Pharmacy and Pharmacology, Physiology, Psychiatry, Public Health, Public Policy, Patient Care and Practice, Sociology, Statistics and Research Methods, Preclinical and Clinical Trials and related subjects.

JAIS will focus on interdisciplinary and translational studies related to: etiology, early detection, disease modifying interventions, and clinical trials of new drugs and neurotech products that can potentially provide preventive and treatment benefits for Alzheimer's patients.

JAIS will have editorial comments about controversies, the principles of neuroscience practice, dementia care, socio-economics, ethics, and topics of interest to our audience.

In addition to accepting research papers from all over the world, JAIS will have contents provided through the meetings of the Alzheimer Society International Congress (ASIC) to be held normally in February/March and September each year. This content, as well as downloads of papers, will be available at no charge. For those stakeholders around the world who cannot afford a journal, or cannot go to ASIC meetings, JAIS will be their source of information.

When papers are accepted, they will be published within days rather than weeks or months. All papers will be searchable through PubMed Central, a division of PubMed, and will be searchable on PubMed and other commonly-used databases.

If you are interested in becoming involved with JAIS in any of its aspects, please contact us at JAIS@alzint.com

Markku Kurkinen and Lloyd L. Tran
Co-Editors-in-Chief
Journal of the Alzheimer International Society



International United Front Against Alzheimer's

STRATEGIC PLAN:

1. Collaborate on the development of prevention and drug treatment therapy for Alzheimer.
2. Accelerate on the development of biomarkers and diagnostics.
3. Harmonize and speed up the AD drug approval processes between regional and international clinical trial systems.
4. Partner with the International Funds Against Alzheimer to raise \$1 Billion to fund new concepts and clinical trials of new Alzheimer drugs with proof of safety and efficacy.
5. Focus resources to bring newly approved drugs to the market by the year 2025.
6. Support the evidenced-based Dementia care practices.

IUFAA is funded by a globally diverse group of private and institutional investors, including foundations, endowments, family offices, financial institutions and pension funds.

Alzheimer International Society serves the coordinating body for the United Front Against Alzheimer's.

For more information, please contact:

Alzheimer International Society

Tel. 1-650-826-2337

www.alzint.com/united.html

SPONSORS & EXHIBITORS



SPONSORS & EXHIBITORS



NeuroActiva, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of new drugs to treat Alzheimer's disease. The clinical trial Phase 2A of NA-831 (Traneurocin) in Alzheimer's patients has shown excellent safety profile with no adverse effects observed. The drug is administered orally in a dosage form for the treatment of Alzheimer's disease. (www.neuroactiva.com)



MagQu Co., Ltd., is an innovative diagnostic company that develops highly sensitive, blood-based assays to detect biomarkers of neurodegenerative diseases including those associated with Alzheimer's Disease (AD) and Parkinson's disease (PD). The company is a pioneer in the application of ImmunoMagnetic Reduction (IMR)-SQUID-based technology to further inform both the biomarker field and clinical care. We are now providing testing services for 7 plasma biomarkers to research laboratory right directly at our testing service company, MagQu LLC, in Phoenix, USA. (<http://www.magqu.com>)



Vielight Inc.: Invented in 1995 in Silicon Valley the intranasal photobiomodulation is a non-invasive method of introducing therapeutic photonic energy into the human body. Vielight is poised at the forefront of brain photobiomodulation technology. Vielight combines science with engineering ingenuity to develop devices that incorporate novel methods of delivering photons to the brain and inner systems. (<https://vielight.com>)



TransPacific Venture Capital Partners, Inc.:

TransPacific has developed deep domain expertise and insight into the biopharmaceutical and biomedical industry. We apply our experience in building great companies to meet the growing need for improved healthcare products and services, resulting in breakthrough therapies and technologies that have transformed the healthcare industry. We focus on novel therapeutics in major disease areas with unmet needs, such as immunotherapy oncology, neurosciences. TransPacific VC Partners, Inc. is the lead investor of United Front Against Alzheimer's (<http://www.transpacificvc.com>)



Whealthcare Planning is a mission-driven company dedicated to helping individuals and families more successfully plan for the financial and emotional challenges associated with aging. We provide a unique cloud-based platform offering a suite of innovative tools and educational materials developed in cooperation with thought leaders in geriatrics, psychiatry, and financial planning. Our platform focuses on preparing individuals and families for major life transitions that virtually all older adults confront (<http://www.whealthcareplan.com>)



eZ-Xpo is a global leader in Virtual Collaborative Network solutions empowering businesses to connect, collaborate, and promote through networks of virtual event marketplaces for lead generation. eZ-Xpo reinvents the trade show and lead generation industry with a revolutionary new approach to virtual events, virtual trade shows, private business networking marketplace, automation to follow up with every prospective customer during and after the event. (<http://www.eZ-Xpo.com>)



AZoNetwork, Ltd. loves telling science, technology and medical stories to monthly addressable audience in excess of 5 million unique individuals. AZoNetwork now provides a highly effective Science Marketing Platform based on its own unique Marketing Science. (<https://www.azonetwork.com>)